Solid Biosciences Inc. (traded on the Nasdaq Global Market under the ticker symbol SLDB) officially went public through its initial public offering (IPO) on January 26, 2018. The life sciences company priced its shares to trade publicly to raise capital for advancing its proprietary gene therapies and Duchenne muscular dystrophy treatment programs.